University of Washington Researcher Details Research in Desmoid Tumor (Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor).

A recent study conducted by researchers at the University of Washington focused on monitoring ovarian function in patients with desmoid tumors. The study, known as DeFi, examined the effects of nirogacestat, a selective gamma secretase inhibitor, on ovarian toxicity (OT) in females of reproductive potential (FORP). The results showed that 75% of FORP treated with nirogacestat experienced OT, but most of these events resolved, suggesting that OT with nirogacestat is transient. The study also highlighted the importance of monitoring ovarian function during oncology clinical trials, although there is currently no scientific consensus on hormone monitoring during cancer therapy or nirogacestat treatment in clinical practice. [Extracted from the article]